Is more better? Increased doses of high dose methotrexate and addition of rituximab is associated with improved outcomes in a large primary CNS lymphoma cohort

BACKGROUND: Primary central nervous system lymphoma (PCNSL) is a rare and aggressive primary brain tumor. While high dose methotrexate (HDMTX) regimens remain standard of care, it remains unclear if optimization of HDMTX doses and the addition of rituximab provide clinical benefit. Over the last 30...

Descripción completa

Detalles Bibliográficos
Autores principales: Yerram, Prakirthi, Reiss, Samantha N., Modelevsky, Lisa, Schaff, Lauren, Reiner, Anne S., Panageas, Katherine S., Grommes, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100595/
https://www.ncbi.nlm.nih.gov/pubmed/37067886
http://dx.doi.org/10.21037/aol-22-19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100595/
https://www.ncbi.nlm.nih.gov/pubmed/37067886
http://dx.doi.org/10.21037/aol-22-19

Ejemplares similares